Nalaganje...
Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
LESSONS LEARNED. Pharmacokinetic results underscore that the vorolanib (X‐82) study design was successful without the need for further dose escalation beyond 400 mg once daily (q.d.). Therefore, the recommended dose of X‐82 as a single agent in patients with advanced cancer is 400 mg q.d. BACKGROUND...
Shranjeno v:
| izdano v: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley & Sons, Inc.
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6459237/ https://ncbi.nlm.nih.gov/pubmed/30478190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0740 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|